Literature DB >> 21763974

Future directions in renal cell carcinoma: 2011 and beyond.

Daniel C Cho1, Michael B Atkins.   

Abstract

Emerging from a largely cytokine-based era, the last several years have witnessed a dramatic change in the therapeutic landscape of renal cancer. Molecularly targeted and antiangiogenic agents now form the backbone of most therapeutic strategies for patients with advanced renal cell carcinoma (RCC). Although the next few years may not see such broad paradigm shifts, there remains significant room for improvement in the care of patients with RCC. This review discusses challenges that face physicians and researchers as well as innovations that may contribute to improving the therapeutic outcomes for patients with RCC.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21763974      PMCID： PMC3151659          DOI： 10.1016/j.hoc.2011.05.001

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  70 in total

1.  Biomarkers: hypertension following anti-angiogenesis therapy.

Authors:  Brian I Rini
Journal:  Clin Adv Hematol Oncol       Date:  2010-06

2.  Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Authors:  D D Sarbassov; David A Guertin; Siraj M Ali; David M Sabatini
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

3.  The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.

Authors:  S Koochekpour; M Jeffers; P H Wang; C Gong; G A Taylor; L M Roessler; R Stearman; J R Vasselli; W G Stetler-Stevenson; W G Kaelin; W M Linehan; R D Klausner; J R Gnarra; G F Vande Woude
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

5.  Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.

Authors:  David C Delgado; Jacquelyn A Hank; Jill Kolesar; David Lorentzen; Jacek Gan; Songwon Seo; Kyungmann Kim; Suzanne Shusterman; Stephen D Gillies; Ralph A Reisfeld; Richard Yang; Brian Gadbaw; Kenneth B DeSantes; Wendy B London; Robert C Seeger; John M Maris; Paul M Sondel
Journal:  Cancer Res       Date:  2010-10-08       Impact factor: 12.701

6.  Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

Authors:  Michael Atkins; Meredith Regan; David McDermott; James Mier; Eric Stanbridge; Amanda Youmans; Philip Febbo; Melissa Upton; Mirna Lechpammer; Sabina Signoretti
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

Review 7.  Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy.

Authors:  Thomas F Gajewski; Jamila Louahed; Vincent G Brichard
Journal:  Cancer J       Date:  2010 Jul-Aug       Impact factor: 3.360

8.  HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors.

Authors:  Farbod Shojaei; Joseph H Lee; Brett H Simmons; Anthony Wong; Carlos O Esparza; Pamela A Plumlee; Junli Feng; Albert E Stewart; Dana D Hu-Lowe; James G Christensen
Journal:  Cancer Res       Date:  2010-10-15       Impact factor: 12.701

9.  Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.

Authors:  David F McDermott; Meredith M Regan; Joseph I Clark; Lawrence E Flaherty; Geoffery R Weiss; Theodore F Logan; John M Kirkwood; Michael S Gordon; Jeffrey A Sosman; Marc S Ernstoff; Christopher P G Tretter; Walter J Urba; John W Smith; Kim A Margolin; James W Mier; Jared A Gollob; Janice P Dutcher; Michael B Atkins
Journal:  J Clin Oncol       Date:  2005-01-01       Impact factor: 44.544

10.  Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib.

Authors:  J C Welti; M Gourlaouen; T Powles; S C Kudahetti; P Wilson; D M Berney; A R Reynolds
Journal:  Oncogene       Date:  2010-11-08       Impact factor: 9.867
View more
  5 in total

1.  A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma.

Authors:  B Rini; B Redman; J A Garcia; H A Burris; S Li; A Fandi; R Beck; U Jungnelius; J R Infante
Journal:  Ann Oncol       Date:  2014-06-08       Impact factor: 32.976

2.  Englerin a selectively induces necrosis in human renal cancer cells.

Authors:  Florian J Sulzmaier; Zhenwu Li; Mika L Nakashige; David M Fash; William J Chain; Joe W Ramos
Journal:  PLoS One       Date:  2012-10-22       Impact factor: 3.240

3.  High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.

Authors:  Xiaoen Wang; Liang Zhang; S Nahum Goldberg; Manoj Bhasin; Victoria Brown; David C Alsop; Sabina Signoretti; James W Mier; Michael B Atkins; Rupal S Bhatt
Journal:  J Transl Med       Date:  2011-12-21       Impact factor: 5.531

4.  Targeted Therapy for Metastatic Renal Carcinoma: an Update.

Authors:  Rodrigo Donalisio da Silva; Diedra Gustafson; Leticia Nogueira; Priya N Werahera; Wilson R Molina; Fernando J Kim
Journal:  J Kidney Cancer VHL       Date:  2014-10-21

5.  Sunitinib resistance in renal cell carcinoma.

Authors:  Christudas Morais
Journal:  J Kidney Cancer VHL       Date:  2014-04-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.